Sectors:
Locations:
Min Investment:
Max Investment:
Target Investment:
Total Funding: $60M
Total Funding: $160M
Total Funding: $35M
Total Funding: $63M
Total Funding: $200M
Total Funding: $470M
Total Funding: $140M
Total Funding: $76M
2012
2022
2012 - 2022
Director, Graphite Bio (GRPH) Director, Century Therapeutics (IPSC) Director, Jnana Therapeutics Director, FirstLight Bio Director, 858 Therapeutics Director, Stablix Director, Nested Therapeutics Director, Pandion Therapeutics (PAND, acquired) Director, Venatorx (2017-2022) Founding CEO, Kyras Therapeutics (2015-2017) Chief Business Officer, Anokion (2014-2017)
2015 - 2022
2015 - 2022
Highline Therapeutics is a biotech incubator established by Versant Ventures in New York City. Modeled on Blueline Bioscience in Toronto, Highline aims to identify and accelerate translational research and biotech company formation. Highline will partner with both local academic institutions and pharmaceutical companies to help bridge the gap between academic science and the development of novel therapeutics.
2010 - 2012
2010 - 2012
Lead global, cross-functional team developing intelligent medicines by integrating electronics and pharmaceuticals to enable remote patient monitoring/e-health applications
2010 - 2010
2010 - 2010
2009 - 2010
2009 - 2010
2002 - 2008
2002 - 2008
2000 - 2002
2000 - 2002